Valneva shares up nearly 14% over three months as they target resistance level
The Lyon-based vaccine company continues its rebound at midday, in a Paris market slightly trending upward. The move follows new data on its chikungunya vaccine, as the share price approaches its medium-term benchmarks.
A rebound that puts the stock in contact with its 50-day moving average
Valneva shares gain 2.32% to 2.65 EUR and rank among the strongest gainers in the SBF 120, which is up 0.33%.
Over the week, the stock is up 6.9%, and over three months it has risen nearly 14%. The price is above the 20-day moving average (2.50 EUR, a gap of 6%) and in contact with the 50-day moving average at 2.65 EUR.
The 200-day moving average, at 2.87 EUR, remains 7.6% above the price: the stock has not yet recovered its long-term benchmark, and it is still down nearly 29% over one year. The RSI at 56 is neutral. The stock is approaching its resistance at 2.71 EUR.
Ixchiq data and an expected decision on the Lyme disease vaccine
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On November 10, Valneva reported new data on its Ixchiq vaccine: the seroresponse rate remains at 94% five years after a single dose.
On November 9, the group published the results of two Phase 2 trials of its candidate against shigellosis, a disease for which no vaccine is approved, and is assessing the development path to follow.
At the release of its H1 2026 results on August 13, the company confirmed its outlook for the year and indicated that it expects regulatory decisions on its candidate against Lyme disease within the next twelve months. Its management will take part in the Jefferies Global Healthcare Conference on November 16.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
EBITDA margin: -60,4 %
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
